Modern Viral Diagnostics & Vaccine Technology|Genomic Tools

Identify the common SARS-CoV-2 infection symptoms, including fever and fatigue, and note headaches, diarrhea, and vomiting observed in many patients.

Clinicians rely on CT imaging to detect infection, revealing bilateral, peripheral ground-glass opacity and diffuse lesions in both lungs, sometimes described as white lungs, in serious cases.

Explore how reverse transcription pcr serves as the gold standard for lab diagnosis, despite 30–60% sensitivity and occasional false positives, versus rapid, specific antibody serodiagnosis using four targeted SARS-CoV-2 proteins.

Contrast antibody tests with rt-pcr, highlighting faster, early diagnosis in basic labs and 70 percent sensitivity, while noting reduced sensitivity in patients over 60 and possible false negatives.

Identify sample sources used for the diagnostic detection of SARS-CoV-2, including nasal and pharyngeal swabs, bronchoalveolar lavage fluid, sputum, blood, and strep.

Discuss CRISPR-based diagnostic tests to enable fast, highly specific detection during pandemics, addressing false negatives in elderly patients. Note the three main CRISPR diagnostic techniques currently used.

Explore ultra-sensitive molecular diagnostic tests for SARS-CoV-2, contrast early tests with rapid point-of-care options, and explain how CRISPR-based diagnostics leverage bacterial defense systems for fast COVID-19 detection.

CRISPR-based diagnostic approach replaces PCR due to long result times, labor-intensive protocols, and dwindling reagents, enabling rapid testing through nucleotide targeting to detect the presence of the wild Ottone.

Explore how CRISPR-based diagnostics gained emergency use authorization during the COVID-19 pandemic, enabling media-certified laboratories to use CRISPR tests to detect SARS-CoV-2.

Explore Sherlock Biosciences' two platforms, Sherlock and Inspector, delivering cost-effective instrument-free diagnostics for infectious diseases, oncology, and agriculture through specific high-sensitivity enzymatic reporter unlocking with a fluorescent readout.

Identify the SARS-CoV-2 target genes discussed and explain how internal controls, including targeting the Ardennes B gene, verify that extraction and testing proceed correctly.

Explore SHERLOCK’s two-step process, using RT-LAMP to reverse transcribe and amplify SARS-CoV-2 RNA, then CRISPR collateral cleavage yields fluorescent signals for rapid, sensitive diagnostics at a constant temperature.

Collect nasal swabs or saliva, extract RNA, then apply guide RNA–based detection targeting the viral genome, producing fluorescence signals read by a detection system.

Explore StopCOVID, a one-step CRISPR SHERLOCK assay that rapidly detects SARS-CoV-2 from saliva or nasal swabs at point-of-care using heating, no extraction, and a simple detection strip.

Compare Sherlock and Inspectr diagnostic platforms, where Sherlock Biosciences uses CRISPR enzyme activity with paper strip or electrochemical readouts, while Inspectr relies on a DNA hybridization sensor with bioluminescent readouts.

Explore a crispr-based detection method from Mammoth Biosciences that uses nasal swabs to identify the virus in about 20 minutes, with no full lab equipment and high sensitivity and specificity.

FELUDA paper strip test uses CRISPR-based detection on a paper strip with saliva or blood. Costs about 500–600 rupees and delivers 45-minute results with 96% sensitivity and 98% specificity.

HybriDetect LFD uses a dipstick with gold nanoparticles to detect different molecules including gene amplification products from PCR, proteins, and antibodies; results can be qualitative or quantitative.

Demonstrate aiod-crispr and pac-man techniques alongside rpa isothermal amplification, highlighting room-temperature, single-tube, low-cost, point-of-care diagnostics that detect RNA and DNA within twenty minutes.

Explore the major challenge of delivering gene editing tools and examine lipid-based delivery, non-toxic synthetic peptides, and nanoparticle carriers that transport nucleotides to target cells for CRISPR applications.

Point of care diagnostics provide near-patient, rapid test results, from blood glucose and cholesterol to covid-19 screens, enabling immediate clinical decisions at home or in clinics.

Explore a rapid point-of-care COVID-19 test using CRISPR-based diagnostics and saliva samples read by a smartphone fluorescence system, delivering results in about 15 minutes.

Explore vaccine development from genome sequencing and target regions through preclinical studies, pharmacokinetics and pharmacodynamics, animal toxicity, and the phase zero to phase four clinical trials plus post marketing surveillance.

Explore how mRNA vaccines use lipid nanoparticles to deliver spike protein instructions, prompting cells to express the spike and generate antibodies, unlike traditional vaccines. Note storage needs and two-dose regimens.